AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39735942 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced monitoring (ECG, Holter monitor, KardiaMobile device)
Number of subjects: 69
Study 39735942 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (ECG and Holter monitor)
Number of subjects: 69
Study 39735948 — intervention group
Group type: EXPERIMENTAL
Intervention: Panvascular disease (PVD)
Number of subjects: 2119
Study 39735948 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 2119
Study 39735948 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity
Number of subjects: 2119
Study 39735948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes
Number of subjects: 2119
Study 39736112 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused lung ultrasound (FLUS) performed by general practitioners (GPs) after a training program.
Number of subjects: 91
Study 39736329 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/kg/day
Number of subjects: 30
Study 39736329 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg/day
Number of subjects: 30
Study 39736329 — intervention group
Group type: COMPARATOR
Intervention: 1.1 g/kg/day
Number of subjects: 30
Study 39736452 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy plus radiotherapy (ICR)
Number of subjects: 702
Study 39736452 — intervention group
Group type: COMPARATOR
Intervention: Immunochemotherapy (IC) alone
Number of subjects: 702
Study 39736452 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy plus radiotherapy (ICR) with definitive dose RT to primary tumor
Number of subjects: 702
Study 39736544 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (PRT)
Number of subjects: 160
Study 39736544 — intervention group
Group type: COMPARATOR
Intervention: Photon radiotherapy (XRT)
Number of subjects: 160
Study 39736611 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG group
Number of subjects: 1564
Study 39736611 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1564
Study 39736611 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1564
Study 39736611 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1564
Study 39736611 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 1564
Study 39736616 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (FURS)
Number of subjects: 414
Study 39736616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Percutaneous Nephrolithotomy (Mini PCNL)
Number of subjects: 414
Study 39736616 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 414
Study 39736619 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed questionnaire assessing perceived physical exertion
Number of subjects: 237
Study 39736619 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed questionnaire
Number of subjects: 237
Study 39736673 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation with load-adjustable gain factors
Number of subjects: 0
Study 39736673 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 0
Study 39736740 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar baits (ATSBs) deployed in March 2022
Number of subjects: 2962
Study 39736740 — intervention group
Group type: EXPERIMENTAL
Intervention: Household survey and bed net usage
Number of subjects: 2962
Study 39736740 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with RDT positivity
Number of subjects: 2962
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-7a-2-3p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-21-5p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-100-5p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-125b-5p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-200b-3p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-200b-5p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-7a-3p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline miRNA-7a2-3p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline miRNA-21-5p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline miRNA-200b-3p
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower bleeding on probing (BOP)
Number of subjects: 21
Study 39736760 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-125b-2-3p
Number of subjects: 21
Study 39736787 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI110 monotherapy (0.01/0.1/0.3/1/3/10/20 mg/kg Q3W)
Number of subjects: 110
Study 39736787 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab (0.3/0.7/1.5/3/5/8/10 mg/kg Q3W + sintilimab 200 mg Q3W)
Number of subjects: 110
Study 39736787 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in sqNSCLC
Number of subjects: 110
Study 39736787 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in GC
Number of subjects: 110
Study 39736868 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with predictive low glucose suspend (SmartGuard)
Number of subjects: 31
Study 39736868 — intervention group
Group type: COMPARATOR
Intervention: User initiated CGM (iscCGM)
Number of subjects: 31
Study 39736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to phthalate esters (DEHP)
Number of subjects: 0
Study 39736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to DEHP metabolites (mono(2-carboxymethylhexyl) phthalate, mono-n-butyl phthalate, monoethylphthalate)
Number of subjects: 0
Study 39736874 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise
Number of subjects: 0
Study 39737062 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born after the last lockdown (March 2020-May 2021)
Number of subjects: 1989
Study 39737062 — intervention group
Group type: COMPARATOR
Intervention: Infants born before the first COVID-19 lockdown (April 2018-March 2020)
Number of subjects: 1989
Study 39737148 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation arm
Number of subjects: 69
Study 39737148 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 69
Study 39737148 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 69
Study 39737328 — intervention group
Group type: EXPERIMENTAL
Intervention: Live group music therapy session + standard care
Number of subjects: 0
Study 39737328 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study 39737396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade), Cladribine, and Rituximab
Number of subjects: 0
Study 39737542 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 116
Study 39737542 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 116
Study 39737577 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional contractions
Number of subjects: 27
Study 39737577 — intervention group
Group type: COMPARATOR
Intervention: Involuntary contractions
Number of subjects: 27
Study 39737579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral camera
Number of subjects: 508
Study 39737579 — intervention group
Group type: COMPARATOR
Intervention: Smartphone
Number of subjects: 508
Study 39737640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (JAK inhibitor) for 16 weeks
Number of subjects: 10
Study 39737816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose emicizumab prophylaxis (2.0-2.5 mg/kg every fortnight for two loading doses, then every 4 weeks) for 8 months
Number of subjects: 15
Study 39737816 — intervention group
Group type: COMPARATOR
Intervention: Low-dose emicizumab prophylaxis
Number of subjects: 15
Study 39737895 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 25
Study 39737899 — intervention group
Group type: EXPERIMENTAL
Intervention: BPX-601 with rimiducid
Number of subjects: 33
Study 39737899 — intervention group
Group type: COMPARATOR
Intervention: BPX-601 without rimiducid
Number of subjects: 33
Study 39737899 — intervention group
Group type: EXPERIMENTAL
Intervention: BPX-601
Number of subjects: 33
Study 39737899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiducid
Number of subjects: 33
Study 39738721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 0
Study 39738721 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: G2min scans
Number of subjects: 38
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: G1min scans
Number of subjects: 38
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: G45s scans
Number of subjects: 38
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: G10min scans
Number of subjects: 38
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: G30s scans
Number of subjects: 38
Study 39738784 — intervention group
Group type: EXPERIMENTAL
Intervention: All scan durations
Number of subjects: 38
Study 39738864 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-based resistance exercise (10 × 10 repetitions of parallel back squats with a 4-s eccentric phase)
Number of subjects: 19
Study 39738864 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-based resistance exercise
Number of subjects: 19
Study 39738874 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus epidermidis in severe AV (0.3%)
Number of subjects: 108
Study 39738874 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus caprae in mild AV (1.5%)
Number of subjects: 108
Study 39738931 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel (TAK-700)
Number of subjects: 10
Study 39738982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - Wheelchair users
Number of subjects: 607
Study 39738982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - Walking aid users
Number of subjects: 607
Study 39738982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - No MAT users
Number of subjects: 607
Study 39738982 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L Mobility Item
Number of subjects: 607
Study 39738982 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 607
Study 39739120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 48
Study 39739120 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 48
Study 39739120 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48
Study 39739195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 3155
Study 39739195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 3155
Study 39739195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3155
Study 39739195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant (both doses)
Number of subjects: 3155
Study 39739628 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5459072 (100 mg b.i.d., 200 mg daily)
Number of subjects: 19
Study 39739628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 39739679 — intervention group
Group type: EXPERIMENTAL
Intervention: DILEU (2 grams daily)
Number of subjects: 34
Study 39739679 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 34
Study 39739679 — intervention group
Group type: COMPARATOR
Intervention: LEU
Number of subjects: 34
Study 39739762 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g twice a day for 14 days)
Number of subjects: 55
Study 39739762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 39739826 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS spectacles (n = 78)
Number of subjects: 234
Study 39739826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine (n = 78)
Number of subjects: 234
Study 39739826 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 78)
Number of subjects: 234
Study 39739907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice-daily
Number of subjects: 489
Study 39739907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice-daily
Number of subjects: 489
Study 39739967 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for anxiety
Number of subjects: 182
Study 39739967 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for mood
Number of subjects: 182
Study 39739967 — intervention group
Group type: COMPARATOR
Intervention: HADS (Hospital Anxiety and Depression Scale)
Number of subjects: 182
Study 39739975 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (IMN) for five days before and seven days after elective surgery
Number of subjects: 0
Study 39739975 — intervention group
Group type: COMPARATOR
Intervention: Routine nutritional care before the operation
Number of subjects: 0
Study 39739975 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 39739976 — intervention group
Group type: EXPERIMENTAL
Intervention: Upamostat (LH011) at doses of 100, 200, 400, or 600 mg daily combined with gemcitabine (1000 mg/m2)
Number of subjects: 17
Study 39739976 — intervention group
Group type: EXPERIMENTAL
Intervention: Upamostat (LH011) at doses of 100 to 600 mg
Number of subjects: 17
Study 39739976 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 17
Study 39739976 — intervention group
Group type: EXPERIMENTAL
Intervention: Upamostat (LH011)
Number of subjects: 17
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) with other antihypertensive therapy (OAHT)
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose prolonged-release tacrolimus (TAC) with or without ACEi/ARB
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) with renin-angiotensin system (RAS) blockade
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) without RAS blockade
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient survival
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft function, blood pressure (BP), and proteinuria
Number of subjects: 281
Study 39739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACEi/ARB in patients randomized initially to OAHT
Number of subjects: 281
Study 39740193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal relationship quality and social support
Number of subjects: 352
Study 39740193 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age and paternal occupation as moderating factors
Number of subjects: 352
Study 39740215 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Lifestyle Medicine Intervention Program-Ontario (CLIP-ON) consisting of 22 weeks of weekly group sessions and monthly individual consultations with physicians, health coaches, kinesiologists, and registered dieticians.
Number of subjects: 10
Study 39740215 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP-ON program
Number of subjects: 10
Study 39740313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib at 60 mg/day (recommended dose)
Number of subjects: 679
Study 39740340 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatGPT
Number of subjects: 122
Study 39740340 — intervention group
Group type: COMPARATOR
Intervention: Manual surveillance
Number of subjects: 122
Study 39740666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide 15 μg/kg daily
Number of subjects: 119
Study 39740667 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-102 phage cocktail
Number of subjects: 19
Study 39740667 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-102 + standard of care (SOC)
Number of subjects: 19
Study 39740667 — intervention group
Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 19
Study 39740667 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-102
Number of subjects: 19
Study 39740941 — intervention group
Group type: EXPERIMENTAL
Intervention: WJ-UC-MSC solution
Number of subjects: 68
Study 39740941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 39740942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g/day, 55% EPA and 37% DHA)
Number of subjects: 4000
Study 39740942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (3200 IU/day)
Number of subjects: 4000
Study 39740942 — intervention group
Group type: COMPARATOR
Intervention: Fish oil and vitamin D trials
Number of subjects: 4000
Study 39740945 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative Arts and Psychomotor Therapies (CAPTs) intervention
Number of subjects: 17
Study 39740951 — intervention group
Group type: EXPERIMENTAL
Intervention: PIT programme (pharmacist reconciliation of medications and structured handoff)
Number of subjects: 14
Study 39740951 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard practices)
Number of subjects: 14
Study 39740955 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 287
Study 39740955 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 287
Study 39740957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Number of subjects: 110
Study 39740957 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 110
Study 39741233 — intervention group
Group type: EXPERIMENTAL
Intervention: CKI combined with first-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Number of subjects: 320
Study 39741233 — intervention group
Group type: COMPARATOR
Intervention: First-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Number of subjects: 320
Study 39741317 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative sedation
Number of subjects: 78
Study 39741323 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR + active-MtCS
Number of subjects: 96
Study 39741323 — intervention group
Group type: COMPARATOR
Intervention: EMDR + sham-MtCS
Number of subjects: 96
Study 39741323 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 96
Study 39741356 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveGames4Change intervention
Number of subjects: 50
Study 39741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab/bevacizumab
Number of subjects: 205
Study 39741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient expectations
Number of subjects: 205
Study 39741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician concordance
Number of subjects: 205
Study 39741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation length
Number of subjects: 205
Study 39741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of life expectancy
Number of subjects: 205
Study 39742012 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Remote Ischemic Preconditioning
Number of subjects: 0
Study 39742012 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 39742013 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Ball intervention, details on dosage and duration not available
Number of subjects: 0
Study 39742013 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 39742454 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message reminder
Number of subjects: 24388
Study 39742454 — intervention group
Group type: COMPARATOR
Intervention: Standard postal reminder letter
Number of subjects: 24388
Study 39742454 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message reminder with recovery strategy (2nd reminder by letter)
Number of subjects: 24388
Study 39742483 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly trained athletes (ATHL)
Number of subjects: 0
Study 39742483 — intervention group
Group type: COMPARATOR
Intervention: Sedentary normal weight (LEAN)
Number of subjects: 0
Study 39742483 — intervention group
Group type: COMPARATOR
Intervention: Sedentary overweight-to-obese (OVWE)
Number of subjects: 0
Study 39742565 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRA+ pre-treatment (n=15)
Number of subjects: 35
Study 39742565 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRA+ post-treatment (n=15)
Number of subjects: 35
Study 39742565 — intervention group
Group type: COMPARATOR
Intervention: IGRA- controls (n=5)
Number of subjects: 35
Study 39742855 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-call format
Number of subjects: 498
Study 39742855 — intervention group
Group type: COMPARATOR
Intervention: In-person format
Number of subjects: 498
Study 39742894 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBRO-Out
Number of subjects: 120
Study 39742894 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBRO-On
Number of subjects: 120
Study 39742894 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study 39742913 — intervention group
Group type: COMPARATOR
Intervention: HFNC at 40 L/min
Number of subjects: 169
Study 39742913 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC at 60 L/min
Number of subjects: 169